• +91-9285106855
  • marketing@zenithdrugs.com
mednext-logomednext-logomednext-logozenith-logo
  • Home
  • About Us
    • Company Profile
    • Mission & Vision
    • Board of Directors
    • Manufacturing
    • Innovations
    • F&D
    • Quality
    • Regulatory
  • Products
    • DOMESTIC
      • Electrolytes (ORS POWDERS)
      • Analgesic - Antipyretic - NSAIDs
      • Anti Inflammatory - Antiemetic
      • Cold - Cough, Antihistaminic & Antiasthmatic
      • Antibacterial - Antifungal
      • Anti-Infective - Ant parasite - Antiviral - Anthelmintic, Anti scabies - Antimicrobial - Antimalarial
      • Disinfectant - Antiseptic - Corticosteriods, Anti Inflammatory - Depigmenting Agent
      • Gastrointestinal - Liver - Kidney
      • Skin Care
      • Antibiotic Preparations
      • Nutrition Supplements
      • Others
    • EXPORT
      • Electrolyte (ORS Powders)
      • Ointment, Cream & Gel
      • Capsules
      • Liquid External
      • Liquid Oral
    • GENERIC DIVISION
      • Biozen
      • RHON-POULE
  • Investors
    • Disclosure u/r 46 of LODR
      • Codes and Policies
        • Code of Conduct for Directors & Senior Management
        • Audit Committee Policy
        • Nomination and Remuneration Committee Policy
        • Stakeholders Relationship Committee Policy
        • Code of Conduct On UPS
        • Code of Fair Disclosure PIT
        • Policy On Whistle Blower & Vigil Mechanism
        • Policy On RPT
        • Policy On Preservation of Documents
        • AntiSexual Harassment Policy
        • Policy On Determining Materiality
        • Code For Independent Directors-main
        • Policy On Familiarisation of Independent Directors
        • Policy on CSR
      • Business Details
      • Board Of Directors
      • Composition of Committees
      • IPO
        • DRHP
        • RHP
        • Prospectus
      • Key Managerial Personnel
      • Annual Report
        • Annual Report Zenith FY 2019-20
        • Annual Report Zenith FY 2020-21
        • Annual Report Zenith FY 2021-22
        • Annual Report Zenith FY 2023-24
      • Annual Returns
        • Annual Returns FY 2017-18
        • Annual Returns FY 2018-19
        • Annual Returns FY 2019-20
        • Annual Returns FY 2020-21
        • Annual Returns FY 2021-22
        • Annual Returns FY 2022-23
        • Annual Returns FY 2023-24
      • Grievance Redressal
    • Others Investor Information
      • MCMD
        • Material Contract
          • Escrow & Sponsor Bank Agreement
          • Market Making Agreement & Addendum
          • MoU Book Built & Addendum
          • RTA Agreement&Addendum
          • Syndicate Agreement
          • Underwriter Agreement&Addendum
        • Material Documents
          • Consents
      • Board Meeting
        • Intimation of Board Meeting-29-05-2024
      • Financial Result
        • Financial Result as on 31-03-2024
        • Financial Results as on 30-09-2024
      • Shareholding Pattern
      • Statutory Disclosure
      • Initial Public Offering
      • Closure of Trading Window
      • Investor Presentation
      • Notice of AGM
      • Postal Ballot
        • Postal Ballot Notice
        • E Voting Result
  • Global Presence
  • Life@Zenith
  • Hiring
  • Contact Us

Hiring

  • Home
  • Hiring
 


Recognitions

Important Links

  • Home
  • About Us
  • Products
  • Investors
  • Global Presence
  • Contact Us

Products

  • ORS Powder
  • Ointment, Cream & Gel
  • Liquid Oral
  • Liquid External

Contact Us

ZENITH DRUGS LIMITED

Registered office:

K. No. 72/5, Village Muradpura
Depalpur, Near Kalaria, Indore,
Madhya Pradesh Pin: 453001
INDIA

Phone: +91-9285106855

Email: marketing@zenithdrugs.com

Website Design By : Creativision